1887

Abstract

Human immunodeficiency virus type 1 (HIV-1) subtype C is the predominant HIV in southern Africa, and is the target of a number of recent vaccine candidates. It has been proposed that a heterologous prime/boost vaccination strategy may result in stronger, broader and more prolonged immune responses. Since HIV-1 Gag Pr55 polyprotein can assemble into virus-like particles (VLPs) which have been shown to induce a strong cellular immune response in animals, we showed that a typical southern African subtype C Pr55 protein expressed in insect cells via recombinant baculovirus could form VLPs. We then used the baculovirus-produced VLPs as a boost to a subtype C HIV-1 DNA prime vaccination in mice. This study shows that a low dose of HIV-1 subtype C Gag VLPs can significantly boost the immune response to a single subtype C DNA inoculation in mice. These results suggest a possible vaccination regimen for humans.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.19396-0
2004-02-01
2021-04-10
Loading full text...

Full text loading...

/deliver/fulltext/jgv/85/2/vir850409.html?itemId=/content/journal/jgv/10.1099/vir.0.19396-0&mimeType=html&fmt=ahah

References

  1. Addo M. M., Yu X. G., Rathod A. and 17 other authors 2003; Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 77:2081–2092
    [Google Scholar]
  2. Amara R. R., Villlinger F., Altman J. D. 19 other authors 2001; Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292:69–74
    [Google Scholar]
  3. Barouch D. H., Craiu A., Kuroda M. J. 19 other authors 2000; Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci U S A 97:4192–4197
    [Google Scholar]
  4. Bojak A., Deml L., Wagner R. 2002; The past, present and future of HIV-vaccine development: a critical view. Drug Discov Today 7:36–46
    [Google Scholar]
  5. Buonaguro L., Buonaguro F. M., Tornesello M. L. 7 other authors; 2001; High efficient production of Pr55 gag virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antivir Res 49:35–47
    [Google Scholar]
  6. Freed E. O. 1998; HIV-1 Gag proteins: diverse functions in the virus life cycle. Virology 251:1–15
    [Google Scholar]
  7. Gaschen B., Taylor J., Yusim K. 8 other authors 2002; Diversity considerations in HIV-1 vaccine selection. Science 296:2354–2360
    [Google Scholar]
  8. Gheysen D., Jacobs E., de Forests F., Thiriart C., Francotte M., Thines D., De Wilde M. 1989; Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected cells. Cell 59:103–112
    [Google Scholar]
  9. Haglund K., Leiner I., Kerksiek K., Buonocore L., Pamer E., Rose J. K. 2002; Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Environ proteins. J Virol 76:7506–7517
    [Google Scholar]
  10. Huang Y., Kong W.-P., Nabel G. J. 2001; Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. J Virol 75:4947–4951
    [Google Scholar]
  11. Jowett J. B. M., Hockley D. J., Nermut M. V., Jones J. M. 1992; Distinct signals in human immunodeficiency virus type 1 Pr55 necessary for RNA binding and particle formation. J Gen Virol 73:3079–3086
    [Google Scholar]
  12. McMichael A., Mwau M., Hanke T. 2002; HIV T cell vaccines, the importance of clades. Vaccine 20:1918–1921
    [Google Scholar]
  13. Mergener K., Fäcke M., Welker R., Brinkmann V., Gelderblom H. R., Kräusslich H.-G. 1992; Analysis of HIV particle formation using transient expression of subviral constructs in mammalian cells. Virology 186:25–39
    [Google Scholar]
  14. Mwau M., McMichael A. J. 2003; A review of vaccines for HIV prevention. J Gene Med 5:3–10
    [Google Scholar]
  15. Nabel G. J. 2002; HIV vaccine strategies. Vaccine 20:1945–1947
    [Google Scholar]
  16. Nermut M. V., Hockley D. J., Jowett J. B. M., Jones I. M., Garreau M., Thomas D. 1994; Fullerene-like organization of HIV Gag-protein shell in virus-like particles produced by recombinant baculovirus. Virology 198:288–296
    [Google Scholar]
  17. Nermut M. V., Zhang W.-H., Francis G., Ciampor F., Morikawa Y., Jones I. M. 2003; Time course of Gag protein assembly in HIV-1-infected cells: a study by immunoelectron microscopy. Virology 305:219–227
    [Google Scholar]
  18. Novitsky V., Cao H., Rybak N. 9 other authors 2002; Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C. J Virol 76:10155–10168
    [Google Scholar]
  19. Overton H. A., Fuji Y., Price I. R., Jones I. M. 1989; The protease and gag gene products of the human immunodeficiency virus: authentic cleavage and post-translational modification in an insect cell expression system. Virology 170:107–116
    [Google Scholar]
  20. Robinson H. L., Montefiori D. C., Johnson P. R. P. 14 other authors 1999; Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 5:526–534
    [Google Scholar]
  21. Royer M., Cerutti M., Gay B., Hong S.-S., Devauchelle G., Boulanger P. 1991; Functional domain of HIV-1 Gag polyprotein expressed in baculovirus-infected cells. Virology 184:417–422
    [Google Scholar]
  22. Royer M., Hong S.-S., Gray V., Cerutti M., Boulanger P. 1992; Expression and extracellular release of human immunodeficiency virus type 1 Gag precursors by recombinant baculovirus-infected cells. J Virol 66:3230–3235
    [Google Scholar]
  23. Shioda T., Shibuta H. 1990; Production of human immunodeficiency virus (HIV)-like particles from cells infected with recombinant vaccinia viruses carrying the gag gene of HIV. Virology 175:139–148
    [Google Scholar]
  24. Shiver J. W., Fu T.-M., Chen L. 49 other authors; 2002; Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415:331–335
    [Google Scholar]
  25. UNAIDS 2002 AIDS Epidemic Update December 2002
    [Google Scholar]
  26. Vajdy M., Gardner J., Neidleman J., Guadra L., Greer C., Perri S. O'Hagan D., Polo J. M. 2001; Human immunodeficiency virus type 1 Gag-specific vagina immunity and protection after local immunizations with sindbis virus-based replicon particles. J Infect Dis 184:1613–1616
    [Google Scholar]
  27. van Baalen C. A., Klein M. R., Huisman R. C. 7 other authors 1996; Fine specificity of cytotoxic T lymphocytes which recognize conserved epitopes of the Gag protein of human immunodeficiency virus type 1. J Gen Virol 77:1659–1665
    [Google Scholar]
  28. van Harmelen J. H., Shephard E., Thomas R., Hanke T., Williamson A.-L., Williamson C. 2003; Construction and characterisation of a candidate HIV-1 subtype C DNA vaccine for South Africa. Vaccine (in press
    [Google Scholar]
  29. Vernon S. K., Murthy S., Wilhelm J., Chanda P. K., Kalyan N., Lee S.-G., Hung P. P. 1991; Ultrastructural characterization of human immunodeficiency virus type 1 Gag-containing particles assembled in a recombinant adenovirus vector system. J Gen Virol 72:1243–1251
    [Google Scholar]
  30. Wee E. G.-T., Patel S., McMichael J., Hanke T. 2002; A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques. J Gen Virol 83:75–80
    [Google Scholar]
  31. Williamson C., Morris L., Maughan M. F. 12 other authors 2003; Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retrovir 19:133–144
    [Google Scholar]
  32. Wills J. W., Craven R. C. 1991; Form, function, and use of retroviral Gag proteins. AIDS 5:639–654
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.19396-0
Loading
/content/journal/jgv/10.1099/vir.0.19396-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error